Male Partner Treatment for Bacterial Vaginosis: A Systematic Review and Meta-Analysis of Randomized Trials.

title: "Male Partner Treatment for Bacterial Vaginosis: What the Meta-Analysis Shows"

description: "A systematic review of eight randomized trials finds routine male partner treatment does not meaningfully change bacterial vaginosis recurrence or cure rates overall, though adherent couples on intensive regimens may fare better."

date: "2025"

studyType: "Systematic review and meta-analysis"

pubmedId: "42861563"

TL;DR

Routine treatment of male partners does not significantly reduce bacterial vaginosis (BV) recurrence or improve cure rates across eight randomized trials (moderate evidence, mixed results). A signal of benefit appears only among fully adherent couples using intensive regimens, which warrants targeted study rather than routine adoption.

What the study found

Bacterial vaginosis is the most common vaginal condition worldwide. It occurs when the typically dominant *Lactobacillus* species give way to an overgrowth of anaerobic bacteria. Standard antibiotic treatment for the woman usually clears symptoms in the short term, but recurrence is common. A growing body of work has suggested that the male genital tract can harbor bacteria associated with BV (BVAB), raising the possibility that untreated partners act as a reservoir for reinfection. That hypothesis motivated trials of concurrent male partner treatment (MPT).

This systematic review and meta-analysis, registered in PROSPERO (CRD420251132582) and conducted under PRISMA guidelines, pooled eight randomized controlled trials published between 1980 and September 2025. Searches covered Embase, Scopus, Google Scholar, and PubMed. Pooled estimates used random-effects models, and risk of bias and certainty of evidence were assessed with RoB 2 and GRADE.

Overall, MPT showed no significant effect on BV recurrence (RR 0.92; 95% CI 0.69 to 1.23; I² = 64%) or on cure rate (RR 1.01; 95% CI 0.94 to 1.07; I² = 46%). The confidence intervals for recurrence are wide and include both meaningful benefit and meaningful harm, and heterogeneity between trials was substantial for recurrence. Adverse events were mild and occurred at similar rates in treated and control groups (RD 0.04; 95% CI 0.02 to 0.11). Partner treatment therefore appears reasonably safe in these trials, though the confidence interval for the adverse event difference does not exclude a small excess.

The authors also looked at adherence. Among couples who were fully adherent, recurrence appeared lower, particularly in a recent trial that combined oral and topical therapy for the male partner. The authors frame this as a hypothesis rather than a finding: the subgroup pattern is suggestive, but adherence is not randomized, and couples who complete treatment may differ in other ways from those who do not. The overall pooled effect of routine partner treatment is neutral, and the review's own conclusion is that a benefit may exist for fully adherent couples on intensive regimens, a question that needs prospective testing.

What this means for you

Routine partner treatment is not established as a standard recurrence-reduction strategy. Across the pooled trials, it did not significantly change recurrence or cure.

Safety looked acceptable in these trials, with adverse events mild and similar between groups.

Adherence and regimen intensity may matter. If partner treatment is considered, the subgroup data suggest that full completion of an intensive regimen is the variable most worth examining, though this remains unproven.

Discuss options with a clinician. Decisions about partner treatment depend on individual history, recurrence pattern, and local guidance, and should not be made from a single meta-analysis.

Study details

Field	Detail
Study type	Systematic review and meta-analysis of randomized controlled trials
Trials included	8
Sample size	Not reported
Registration	PROSPERO CRD420251132582
Search period	1980 to September 2025
Databases	Embase, Scopus, Google Scholar, PubMed
Primary outcomes	BV recurrence (RR 0.92), BV cure (RR 1.01)
Adverse events	RD 0.04 (95% CI 0.02 to 0.11)
Journal	Sexually Transmitted Diseases
PubMed ID	42861563

Sources

1. Systematic review and meta-analysis of randomized controlled trials on male partner treatment for bacterial vaginosis. *Sexually Transmitted Diseases*. PubMed. https://pubmed.ncbi.nlm.nih.gov/42861563/

ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.